Literature DB >> 9642242

C5 convertase of the alternative pathway of complement. Kinetic analysis of the free and surface-bound forms of the enzyme.

N Rawal1, M K Pangburn.   

Abstract

Although proteolytic activation of the complement protein C5 initiates important defensive and occasionally pathological inflammatory reactions, the enzymatic properties of the enzymes responsible for this cleavage have never been examined. We have studied the kinetic parameters of the C5 convertase of the alternative pathway of complement, either bound to a zymosan surface or in its monomeric soluble form. C5 convertase enzymatic activity was measured as a function of C5 concentration by quantitating production of C5b,6 under physiological conditions of temperature, pH, and ionic strength. The C5 convertases appeared to follow Michaelis-Menten kinetics and exhibited similar catalytic rate constants (kcat). However, the surface-bound enzyme, ZymC3b,Bb had a Km (1.4 microM) that was 17 times lower than that of the soluble monomeric form of the enzyme, C3b,Bb (Km = 24 microM). The kcat for the cell-bound enzyme, ZymC3b,Bb was 0.0048 s-1 and that for soluble C3b,Bb was 0.0110 s-1. Both forms of the enzyme had a low turnover number at Vmax (0.23 to 0.68 C5/min/enzyme). Substituting Mg2+ for Ni2+ did not alter the kinetic parameters but lowered the half-life of the enzyme by 5-7-fold. The kinetic data presented demonstrate that the fluid phase C5 convertase, C3b,Bb, can cleave C5 without the aid of a second C3b molecule. The results also show that the greater enzymatic activity previously observed for the surface-bound C5 convertases is not due to higher catalytic efficiency but is solely due to higher affinity for the substrate C5. In blood, C5 concentrations are 3-4-fold below the Km determined for the surface-bound C5 convertase suggesting a direct correlation between the local C5 concentration and production of the anaphylatoxin C5a and the cytolytic C5b-9 complex.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9642242     DOI: 10.1074/jbc.273.27.16828

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.

Authors:  E Jelezarova; A Vogt; H U Lutz
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

2.  Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement.

Authors:  Kenneth J Katschke; Scott Stawicki; Jianping Yin; Micah Steffek; Hongkang Xi; Lizette Sturgeon; Philip E Hass; Kelly M Loyet; Laura Deforge; Yan Wu; Menno van Lookeren Campagne; Christian Wiesmann
Journal:  J Biol Chem       Date:  2009-02-05       Impact factor: 5.157

3.  Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy.

Authors:  Marieta M Ruseva; Tao Peng; Melissa A Lasaro; Keith Bouchard; Susan Liu-Chen; Fang Sun; Zhao-Xue Yu; Andre Marozsan; Yi Wang; Matthew C Pickering
Journal:  J Am Soc Nephrol       Date:  2015-06-05       Impact factor: 10.121

4.  Intramembrane proteolysis of β-amyloid precursor protein by γ-secretase is an unusually slow process.

Authors:  Frits Kamp; Edith Winkler; Johannes Trambauer; Amelie Ebke; Regina Fluhrer; Harald Steiner
Journal:  Biophys J       Date:  2015-03-10       Impact factor: 4.033

5.  Polyphosphate suppresses complement via the terminal pathway.

Authors:  Jovian M Wat; Jonathan H Foley; Michael J Krisinger; Linnette Mae Ocariza; Victor Lei; Gregory A Wasney; Emilie Lameignere; Natalie C Strynadka; Stephanie A Smith; James H Morrissey; Edward M Conway
Journal:  Blood       Date:  2013-12-13       Impact factor: 22.113

Review 6.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

7.  Stringent regulation of complement lectin pathway C3/C5 convertase by C4b-binding protein (C4BP).

Authors:  Nenoo Rawal; Rema Rajagopalan; Veena P Salvi
Journal:  Mol Immunol       Date:  2009-08-05       Impact factor: 4.407

8.  Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O).

Authors:  Gurpanna Saggu; Claudio Cortes; Heather N Emch; Galia Ramirez; Randall G Worth; Viviana P Ferreira
Journal:  J Immunol       Date:  2013-05-15       Impact factor: 5.422

Review 9.  Properdin in complement activation and tissue injury.

Authors:  Allison M Lesher; Bo Nilsson; Wen-Chao Song
Journal:  Mol Immunol       Date:  2013-06-29       Impact factor: 4.407

10.  Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor.

Authors:  Suzan H M Rooijakkers; Jin Wu; Maartje Ruyken; Robert van Domselaar; Karel L Planken; Apostolia Tzekou; Daniel Ricklin; John D Lambris; Bert J C Janssen; Jos A G van Strijp; Piet Gros
Journal:  Nat Immunol       Date:  2009-06-07       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.